PIR and renal cell adenocarcinoma: To discern the specific pathway involved in piR‐RCC‐induced YBX‐1 phosphorylation in RCC, RSK inhibitor (SL0101), PI3K‐AKT pathway inhibitors (API‐2 and LY290042), and p‐ERK1/2 inhibitor (PD980059) were employed to treat RCC cells.[23, 36, 37, 38, 39] Western blot assay revealed that API‐2 and LY290042, two PI3K‐AKT pathway inhibitors, notably reduced the p‐YBX‐1 (S102) level in RCC cells, while RSK and ERK1/2 inhibitors exhibited negligible impact on its expression (Figure 4K).